Armata Pharmaceuticals (ARMP) Non Operating Interest Expenses (2013 - 2026)

Armata Pharmaceuticals has disclosed Non Operating Interest Expenses across 13 years of filings, most recently posting $6.6 million for Q2 2026.

• In Q2 2026, Non Operating Interest Expenses rose 74.21% year-over-year to $6.6 million; the TTM figure through Jun 2026 stood at $21.4 million (up 57.0% YoY), while the FY2025 annual figure was $16.6 million, up 54.44% from the prior year.
• Non Operating Interest Expenses came in at $6.6 million for Q2 2026 at Armata Pharmaceuticals, up from $5.6 million in the prior quarter.
• In the past five years, Non Operating Interest Expenses ranged from a high of $6.6 million in Q2 2026 to a low of $1.2 million in Q3 2023.
• Average Non Operating Interest Expenses over 4 years is $3.5 million, with a median of $3.4 million recorded in 2024.
• Year-over-year, Non Operating Interest Expenses soared 148.55% in 2024 and jumped 40.1% in 2025.
• Over 4 years, Non Operating Interest Expenses stood at $1.4 million in 2023, then surged by 126.21% to $3.3 million in 2024, then soared by 47.38% to $4.8 million in 2025, then surged by 37.24% to $6.6 million in 2026.
• Per Business Quant data, the three most recent Non Operating Interest Expenses figures were $6.6 million in Q2 2026, $5.6 million in Q1 2026, and $4.8 million in Q4 2025.